Core Viewpoint - The U.S. CDC has adopted new recommendations for RSV vaccinations, lowering the age for eligible recipients, which has positively impacted Moderna's stock price and expanded its market potential for the RSV vaccine, mResvia [1][7]. Group 1: CDC Recommendations - The CDC has revised its recommendations to include adults aged 50-59 at higher risk of severe illness from RSV, advising them to receive a single dose of the vaccine [2][8]. - Previously, the guidance recommended vaccination for individuals aged 75 and older, and those aged 60-74 who were at high risk [2][8]. - The current HHS secretary, Robert F. Kennedy, Jr., officially adopted these recommendations, filling the role of CDC director, which is currently vacant [3]. Group 2: Impact on Moderna - The expanded CDC recommendations increase the addressable market for Moderna's RSV vaccine, mResvia, by including a new segment of eligible patients aged 50-59 [7][8]. - Despite the initial approval of mResvia for individuals aged 60 and older, the FDA recently expanded its label to include high-risk individuals aged 18-59 [9]. - Sales of mResvia have been modest since its commercial launch last year, as it was approved later in the contracting season compared to GSK's and Pfizer's vaccines [9][10]. Group 3: Competitive Landscape - Moderna is competing with GSK and Pfizer, both of which have already received approvals for their RSV vaccines for individuals aged 60 and older, with GSK's Arexvy also approved for high-risk individuals aged 50-59, and Pfizer's Abrysvo approved for high-risk individuals aged 18-59 [11]. - The earlier availability of GSK and Pfizer's vaccines has given them a dominant position in the market over Moderna [10]. Group 4: Stock Performance - Year to date, Moderna's stock has lost 27%, while the industry has only seen a 2% decline [5].

Key Takeaways Moderna's mRNA-1010 flu shot showed 26.6% better efficacy than GSK's in a phase III trial. Efficacy was strong across strains and age groups, with 27.4% rVE in seniors aged 65 and older. The results may aid future FDA submissions for mRNA-1010 and support the combo vaccine mRNA-1083.Moderna (MRNA) announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc (GSK) in a phase III efficacy stu ...

Group 1 - Apple is considering abandoning its self-developed AI models and may use AI technologies from Anthropic or OpenAI for the new version of Siri, indicating that its internal progress in AI may not meet expectations [2][3] Group 2 - Moderna announced that its experimental mRNA-based flu vaccine produced a stronger immune response than existing vaccines in a Phase 3 trial, paving the way for the approval of its COVID-19/flu combination vaccine [4][5] Group 3 - Google is increasing its investment in the nuclear fusion startup Commonwealth Fusion Systems (CFS) and has signed a power purchase agreement with the company, aiming to develop and expand clean and safe fusion energy [5][6] Group 4 - A research team from the National University of Singapore has developed a new type of perovskite organic tandem solar cell, achieving a world record light-to-electricity conversion efficiency of 26.4% over an effective area of 1 square centimeter, with potential applications in drones and wearable devices [6][7] Group 5 - Meta's CEO Mark Zuckerberg announced a major restructuring of the company's AI team, creating a "Superintelligence Lab" (MSL) that will encompass various teams focused on developing open-source Llama software and foundational AI research projects [7][8]

Clinical Trial Results - Moderna 的 mRNA 流感疫苗候选产品在后期试验中显示出积极结果 [1] Stock Market Performance - Moderna 的股票在试验结果公布后上涨 [1]

凤凰网财经讯 6月30日，美股三大指数集体高开，道指涨0.5%，纳指涨0.43%，标普500指数涨0.32%。 【Strategy上周斥资约5.319亿美元增持4980枚比特币】 据官方消息，Strategy（原MicroStrategy）在6月23日至6月29日期间以每枚约106,801美元的价格，斥资 约5.319亿美元购入4,980枚比特币；截至2025年年初至今，其比特币投资收益率已达19.7%。截至2025 年6月29日，该公司持有597,325枚比特币，这些比特币是以每枚约70,982美元的价格购入，总成本约424 亿美元。 【零部件供应不足 丰田旗下大发汽车将暂停日本部分工厂运营】 丰田旗下大发汽车6月30日公告称，由于供应商零部件供应不足，大发汽车旗下日本整车工厂将暂停以 下运营：7月8日至11日，暂停滋贺第二工厂运营；7月7日至11日暂停大分中津第二工厂运营。 慧与科技涨超11%，美国司法部解决了公司以140亿美元收购Juniper Networks的反垄断案件；甲骨文涨 超7%，公司CEO称2026财年取得强劲开局，签署了多项大型云服务协议。Moderna涨超4%，高盛涨超 3%。 公司消 ...

Moderna美股盘前涨超6%，此前公司宣布实验性流感疫苗达到三期临床试验主要终点。 | 品、◎ ■× ◎ ▽ VS FID ■ | 资讯 · | 评论 · | Moderna 分时 v 1天:1分K v | 报价 | 分析 | 中 ノ ▽ ▽ ▽ ▽ ▽ ▽ ▽ ▽ ▽ ▽ △ ▽ △ | 0 @ | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (0) | MRNA Moderna | 最高价 29. 盘前分时 ~ ○ ○ (+ | 盘前总额 81.67万 | 盘前总量 2.89万 | | | | | | | | | | | | | 27.1604-0.380 -1.38% | 收盘价 06/27 15:59 美东 | 28.850 | 6.22% | 盘前价 06/30 07:14 美东 | 28.650 t 1.490 +5.49% | | | | | | | | | | | | 5.83% | 28.744 | 四 ...

Core Insights - Moderna's experimental mRNA-based flu vaccine has shown a stronger immune response compared to the currently available vaccine in late-stage trials, paving the way for further development of both the flu vaccine and a combination flu and Covid jab [1][3]. Company Developments - In May, Moderna voluntarily withdrew its application for the combination vaccine targeting Covid-19 and influenza, planning to resubmit it with efficacy data from the phase three trial of its standalone flu vaccine [2]. - The company intends to resubmit the application for the combination vaccine and seek approval for its standalone flu shot later this year, with expectations for regulatory approvals for both products next year [3]. Market Position - Moderna is currently a frontrunner against competitors Pfizer and Novavax in the race to market a combination vaccine, with the potential for significant revenue from the multi-billion-dollar markets of Covid, flu, and respiratory syncytial virus [4][5]. Efficacy Data - The phase three trial involved over 40,000 adults aged 50 and above, showing that Moderna's mRNA-1010 vaccine was 26.6% more effective than the standard competitor vaccine [5]. - The mRNA-1010 vaccine demonstrated strong efficacy against major influenza strains, with a 27.4% higher effectiveness in adults aged 65 and older compared to the standard flu vaccine [6]. Public Health Context - Moderna's CEO highlighted the importance of effective vaccines, especially given that flu-related hospitalizations reached a 15-year high during the 2024 to 2025 season, with over 600,000 hospitalizations reported [7]. Safety and Regulatory Engagement - The safety data for the mRNA-1010 vaccine aligns with previous phase three study results, indicating a consistent safety profile [8]. - Moderna is actively engaging with the FDA to clarify regulatory requirements and believes it has a clear path regarding flu vaccine approval [9].

Company Performance - Moderna's stock closed at $27.54, reflecting a +2.53% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.8% [1] - Over the past month, shares of Moderna have increased by 3.11%, while the Medical sector gained 3.12% and the S&P 500 gained 5.12% [1] Upcoming Earnings - Analysts expect Moderna to report an EPS of -$2.97, which is a 10.81% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $130.15 million, down 46% from the same period last year [2] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$9.81 and revenue of $2.08 billion, indicating changes of -10.6% and -35.83% respectively from the previous year [3] - Recent changes to analyst estimates for Moderna suggest a favorable outlook on the company's business health and profitability [3] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 86, placing it in the top 35% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Moderna (MRNA) ended the recent trading session at $25.90, demonstrating a +1.97% change from the preceding day's closing price. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq depreciated by 0.51%. Coming into today, shares of the biotechnology company had lost 4.94% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 0.45%. Market participants will be closely following the financial r ...

Intismeran autogene (mRNA-4157) - mRNA-4157 is designed to target an individual patient's unique tumor mutation [6] - mRNA-4157 is in Phase 3 study for adjuvant melanoma, which is fully enrolled [6] - mRNA-4157 is in two adjuvant Phase 3 studies for NSCLC, for those with and without prior neoadjuvant treatment [6] - mRNA-4157 is in randomized Phase 2 study for adjuvant high-risk muscle invasive bladder cancer and adjuvant renal cell carcinoma, the latter of which is fully enrolled [6] - mRNA-4157 is in randomized Phase 2 study for high-risk non-muscle invasive bladder cancer (HR NMIBC) [6] - mRNA-4157 is in Phase 1 basket study for solid tumors: Melanoma, Gastric, PDAC, NSCLC [6] Off-the-shelf cancer antigen therapies - mRNA-4359 targets immunosuppressive cells and mechanisms [10] - mRNA-4359 is in Phase 2, with additional indications planned [10, 11] - mRNA-4106 is in Phase 1 [10] - mRNA-4359 encodes for PD-L1 and IDO, targeting both immunosuppressive cells and cancer cells, and is applicable to many different cancer types [15] T-cell engagers - The company is developing two approaches with secreted T-cell engaging antibodies to target surface and intracellular proteins [19] In vivo cell therapy - mRNA-4203 (partnered with Immatics) has an IND open [28]